Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'COAGULATION-FACTOR-IX' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 141 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Favre, D; Provost, N; Blouin, V; Blacho, G; Cherel, Y; Salvetti, A; Moullier, P
      Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle

      MOLECULAR THERAPY
    2. Arruda, VR; Fields, PA; Milner, R; Wainwright, L; De Miguel, MP; Donovan, PJ; Herzog, RW; Nichols, TC; Biegel, JA; Razavi, M; Dake, M; Huff, D; Flake, AW; Couto, L; Kay, MA; High, KA
      Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males

      MOLECULAR THERAPY
    3. Nicklin, SA; Buening, H; Dishart, KL; de Alwis, M; Girod, A; Hacker, U; Thrasher, AJ; Ali, RR; Hallek, M; Baker, AH
      Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells

      MOLECULAR THERAPY
    4. Herzog, RW; Mount, JD; Arruda, VR; High, KA; Lothrop, CD
      Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation

      MOLECULAR THERAPY
    5. Fields, PA; Arruda, VR; Armstrong, E; Chu, K; Mingozzi, F; Hagstrom, JN; Herzog, RW; High, KA
      Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9

      MOLECULAR THERAPY
    6. Chao, HJ; Monahan, PE; Liu, YB; Samulski, RJ; Walsh, CE
      Sustained and complete phenotype correction of hemophilia B mice followingintramuscular injection of AAV1 serotype vectors

      MOLECULAR THERAPY
    7. Fewell, JG; MacLaughlin, F; Mehta, V; Gondo, M; Nicol, F; Wilson, E; Smith, LC
      Gene therapy for the treatment of hemophilia B using PINC-formulated plasmid delivered to muscle with electroporation

      MOLECULAR THERAPY
    8. Liras, A
      Gene therapy for haemophilia: the end of a 'royal pathology' in the third millennium?

      HAEMOPHILIA
    9. Josic, D; Kannicht, C; Loster, K; Pock, K; Iberer, G; Buchacher, A
      Vitronectin in clotting factor IX concentrates

      HAEMOPHILIA
    10. High, KA
      Gene therapy: a 2001 perspective

      HAEMOPHILIA
    11. Sarukhan, A; Soudais, C; Danos, O; Jooss, K
      F;actors influencing cross-presentation of non-self antigens expressed from recombinant adeno-associated virus vectors

      JOURNAL OF GENE MEDICINE
    12. Chuah, MKL; Collen, D; VandenDriessche, T
      Gene therapy for hemophilia

      JOURNAL OF GENE MEDICINE
    13. Donahue, RE; Dunbar, CE
      Update on the use of nonhuman primate models for preclinical testing of gene therapy approaches targeting hematopoietic cells

      HUMAN GENE THERAPY
    14. Xu, LF; Daly, T; Gao, CH; Flotte, TR; Song, SH; Byrne, BJ; Sands, MS; Ponder, KP
      CMV-beta-actin promoter directs higher expression from an adeno-associatedviral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice

      HUMAN GENE THERAPY
    15. Fields, PA; Armstrong, E; Hagstrom, JN; Arruda, VR; Murphy, ML; Farrell, JP; High, KA; Herzog, RW
      Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice

      GENE THERAPY
    16. Song, S; Embury, J; Laipis, PJ; Berns, KI; Crawford, JM; Flotte, TR
      Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors

      GENE THERAPY
    17. Lefkowitz, JB; Nuss, R; Haver, T; Jacobson, L; Thompson, AR; Manco-Johnson, M
      Factor IX Denver, ASN 346 -> ASP mutation resulting in a dysfunctional protein with defective factor VIIIa interaction

      THROMBOSIS AND HAEMOSTASIS
    18. White, GC
      Gene therapy in hemophilia: Clinical trials update

      THROMBOSIS AND HAEMOSTASIS
    19. Tomokiyo, K; Teshima, K; Nakatomi, Y; Watanabe, T; Mizuguchi, J; Nozaki, C; Nakagaki, T; Miyamoto, S; Funatsu, A; Iwanaga, S
      Induction of acquired factor IX inhibitors in cynomolgus monkey (Macaca fascicularis): A new primate model of hemophilia B

      THROMBOSIS RESEARCH
    20. Kogan, AE; Kardakov, DV; Khanin, MA
      Analysis of the activated partial thromboplastin time test using mathematical modeling

      THROMBOSIS RESEARCH
    21. Nakai, H; Yant, SR; Storm, TA; Fuess, S; Meuse, L; Kay, MA
      Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo

      JOURNAL OF VIROLOGY
    22. Halbert, CL; Allen, JM; Miller, AD
      Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors

      JOURNAL OF VIROLOGY
    23. Sarukhan, A; Camugli, S; Gjata, B; von Boehmer, H; Danos, O; Jooss, K
      Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors

      JOURNAL OF VIROLOGY
    24. Bajaj, SP; Schmidt, AE; Mathur, A; Padmanabhan, K; Zhong, DG; Mastri, M; Fay, PJ
      Factor IXa : factor VIIIA interaction - Helix 330-338 of factor IX interacts with residues 558-565 and spatially adjacent regions of the A2 subunit of factor VIIIa

      JOURNAL OF BIOLOGICAL CHEMISTRY
    25. Watzke, HH
      Gene therapy for hemophilia

      INTERNIST
    26. High, KA
      Gene transfer as an approach to treating hemophilia

      CIRCULATION RESEARCH
    27. Ponnazhagan, S; Curiel, DT; Shaw, DR; Alvarez, RD; Siegal, GP
      Adeno-associated virus for cancer gene therapy

      CANCER RESEARCH
    28. Nathwani, AC; Davidoff, A; Hanawa, H; Zhou, JF; Vanin, EF; Nienhuis, AW
      Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA

      BLOOD
    29. Ge, Y; Powell, S; Van Roey, M; McArthur, JG
      Factors influencing the development of an anti-factor IX (FIX) response following administration of adeno-associated virus-FIX

      BLOOD
    30. Tran, ND; Porada, CD; Almeida-Porada, G; Glimp, HA; Anderson, WF; Zanjani, ED
      Induction of stable prenatal tolerance to beta-galactosidase by in utero gene transfer into preimmune sheep fetuses

      BLOOD
    31. Arruda, VR; Hagstrom, JN; Deitch, J; Heiman-Patterson, T; Camire, RM; Chu, K; Fields, PA; Herzog, RW; Couto, LB; Larson, PJ; High, KA
      Posttranslational modifications of recombinant myotube-synthesized human factor IX

      BLOOD
    32. Hsu, YC; Hamaguchi, N; Chang, YJ; Lin, SW
      The distinct roles that Gln-192 and Glu-217 of factor IX play in selectivity for macromolecular substrates and inhibitors

      BIOCHEMISTRY
    33. Miao, CH; Ohashi, K; Patijn, GA; Meuse, L; Ye, X; Thompson, AR; Kay, MA
      Inclusion of the hepatic locus control region, an intron, and untranslatedregion increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro

      MOLECULAR THERAPY
    34. Chen, SJ; Tazelaar, J; Moscioni, AD; Wilson, JM
      In vivo selection of hepatocytes transduced with adeno-associated viral vectors

      MOLECULAR THERAPY
    35. Xiao, WD; Chirmule, N; Schnell, MA; Tazelaar, J; Hughes, JV; Wilson, JM
      Route of administration determines induction of T-cell-independent humoralresponses to adeno-associated virus vectors

      MOLECULAR THERAPY
    36. White, GC; Roberts, HR
      Gene therapy for hemophilia: A step closer to reality

      MOLECULAR THERAPY
    37. Fields, PA; Kowalczyk, DW; Arruda, VR; Armstrong, E; McCleland, ML; Hagstrom, JN; Pasi, KJ; Ertl, HCJ; Herzog, RW; High, KA
      Role of vector in activation of T cell subsets in immune responses againstthe secreted transgene product factor IX

      MOLECULAR THERAPY
    38. Wang, LL; Nichols, TC; Read, MS; Bellinger, DA; Verma, IM
      Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver

      MOLECULAR THERAPY
    39. Allen, JM; Halbert, CL; Miller, AD
      Improved adeno-associated virus vector production with transfection of a single helper adenovirus gene, E4orf6

      MOLECULAR THERAPY
    40. Hortelano, G; Ofosu, FA
      Therapeutic approaches for haemophilia

      EXPERT OPINION ON THERAPEUTIC PATENTS
    41. Pruthi, RK; Heit, JA; Green, MM; Emiliusen, LM; Nichols, WL; Wilke, JL; Gastineau, DA
      Venous thromboembolism after hip fracture surgery in a patient with haemophilia B and factor V Arg506Gln (factor V Leiden)

      HAEMOPHILIA
    42. Holoshitz, N; Kurachi, K; Kurachi, S
      Carrier analysis of a moderately affected haemophilia B family

      HAEMOPHILIA
    43. Athanasopoulos, T; Fabb, S; Dickson, G
      Gene therapy vectors based on adeno-associated virus: Characteristics and applications to acquired and inherited diseases (Review)

      INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
    44. Carter, PJ; Samulski, RJ
      Adeno-associated viral vectors as gene delivery vehicles (review)

      INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
    45. Nakai, H; Storm, TA; Kay, MA
      Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors

      NATURE BIOTECHNOLOGY
    46. Tal, J
      Adeno-associated virus-based vectors in gene therapy

      JOURNAL OF BIOMEDICAL SCIENCE
    47. Xu, XL; Liu, QL; Wu, SD
      The binding of the anticoagulation factor I from the venom Agkistrodon acutus to activated factor X

      CHINESE SCIENCE BULLETIN
    48. Oka, K; Davis, AR; Chan, L
      Recent advances in liver-directed gene therapy: implications for the treatment of dyslipidemia

      CURRENT OPINION IN LIPIDOLOGY
    49. Suggett, S; Kirchhofer, D; Hass, P; Lipari, T; Moran, P; Nagel, M; Judice, K; Schroeder, K; Tom, J; Lowman, H; Adams, C; Eaton, D; Devaux, B
      Use of phage display for the generation of human antibodies that neutralize factor IXa function

      BLOOD COAGULATION & FIBRINOLYSIS
    50. Wu, PC; Hamaguchi, N; Yu, YS; Shen, MC; Lin, SW
      Hemophilia B with mutations at glycine-48 of factor IX exhibited delayed activation by the factor VIIa-tissue factor complex

      THROMBOSIS AND HAEMOSTASIS
    51. Ozawa, K; Fan, DS; Shen, Y; Muramatsu, S; Fujimoto, K; Ikeguchi, K; Ogawa, M; Urabe, M; Kume, A; Nakano, I
      Gene therapy of Parkinson's disease using Adeno-Associated Virus (AAV) vectors

      JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT
    52. Takahashi, I; Kojima, T; Sano, M; Watanabe, T; Kamiya, T; Saito, H
      Detailed characterization of an anti-factor IX monoclonal antibody that neutralizes the prolonged ox brain prothrombin time of hemophilia B-M by synthetic peptides

      PEPTIDES
    53. Loukas, A; Maizels, RM
      Helminth C-type lectins and host-parasite interactions

      PARASITOLOGY TODAY
    54. Peng, DC; Qian, C; Sun, YL; Barajas, MA; Prieto, J
      Transduction of hepatocellular carcinoma (HCC) using recombinant adeno-associated virus (rAAV): in vitro and in vivo effects of genotoxic agents

      JOURNAL OF HEPATOLOGY
    55. Emilien, G; Maloteaux, JM; Penasse, C; Goodeve, A; Casimir, C
      Haemophilias: advances towards genetic engineering replacement therapy

      CLINICAL AND LABORATORY HAEMATOLOGY
    56. Shin, Y; Okuyama, I; Hasegawa, J; Morita, T
      Molecular cloning of glycoprotein Ib-binding protein, flavocetin-A, which inhibits platelet aggregation

      THROMBOSIS RESEARCH
    57. Nakai, H; Storm, TA; Kay, MA
      Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo

      JOURNAL OF VIROLOGY
    58. Neels, JG; van den Berg, BMM; Mertens, K; ter Maat, H; Pannekoek, H; van Zonneveld, AJ; Lenting, PJ
      Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein

      BLOOD
    59. London, FS; Walsh, PN
      Zymogen factor IX potentiates factor IXa-catalyzed factor X activation

      BIOCHEMISTRY
    60. Schneider, H; Adebakin, S; Themis, M; Cook, T; Douar, AM; Pavirani, A; Coutelle, C
      Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: A model for the prenatal treatment of haemophilia B

      JOURNAL OF GENE MEDICINE
    61. Eisensmith, RC; Kuzmin, AI; Krougliak, VA
      Prospects for the treatment of phenylketonuria by gene therapy

      MENTAL RETARDATION AND DEVELOPMENTAL DISABILITIES RESEARCH REVIEWS
    62. Snyder, RO; Miao, C; Meuse, L; Tubb, J; Donahue, BA; Lin, HF; Stafford, DW; Patel, S; Thompson, AR; Nichols, T; Read, MS; Bellinger, DA; Brinkhous, KM; Kay, MA
      Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors

      NATURE MEDICINE
    63. Montejo, JM; Magallon, M; Tizzano, E; Solera, J
      Identification of twenty-one new mutations in the factor IX gene by SSCP analysis

      HUMAN MUTATION
    64. Hoag, H; Gore, J; Barry, D; Mueller, CR
      Gene therapy expression vectors based on the clotting Factor IX promoter

      GENE THERAPY
    65. Conway, JE; ap Rhys, CMJ; Zolotukhin, I; Zolotukhin, S; Muzyczka, N; Hayward, GS; Byrne, BJ
      High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap

      GENE THERAPY
    66. Enjolras, N; Rodriguez, MH; Plantier, JL; Attali, O; Negrier, C
      The three in-frame ATG, clustered in the translation initiation sequence of human factor IX gene, are required for an optimal protein production

      THROMBOSIS AND HAEMOSTASIS
    67. Mertens, K; Celie, PHN; Kolkman, JA; Lenting, PJ
      Factor VIII-factor IX interactions: Molecular sites involved in enzyme-cofactor complex assembly

      THROMBOSIS AND HAEMOSTASIS
    68. Bajaj, SP
      Region of factor IXa protease domain that interacts with factor VIIIa: Analysis of select hemophilia B mutants

      THROMBOSIS AND HAEMOSTASIS
    69. Herzog, RW; High, KA
      Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy

      THROMBOSIS AND HAEMOSTASIS
    70. Patijn, GA; Kay, MA
      Hepatic gene therapy using adeno-associated virus vectors

      SEMINARS IN LIVER DISEASE
    71. Finn, BE; Drakenberg, T
      Calcium-binding proteins

      ADVANCES IN INORGANIC CHEMISTRY, VOL 46
    72. Wang, LL; Takabe, K; Bidlingmaier, SM; Ill, CR; Verma, IM
      Sustained correction of bleeding disorder in hemophilia B mice by gene therapy

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    73. Burton, M; Nakai, H; Colosi, P; Cunningham, J; Mitchell, R; Couto, L
      Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    74. Kay, MA; High, K
      Gene therapy for the hemophilias

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    75. Nakai, H; Iwaki, Y; Kay, MA; Couto, LB
      Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver

      JOURNAL OF VIROLOGY
    76. Mizuno, H; Fujimoto, Z; Koizumi, M; Kano, H; Atoda, H; Morita, T
      Crystal structure of coagulation factor IX-binding protein from habu snakevenom at 2.6 angstrom: Implication of central loop swapping based on deletion in the linker region

      JOURNAL OF MOLECULAR BIOLOGY
    77. Mathus, A; Bajaj, SP
      Protease and EGF1 domains of factor IXa play distinct roles in binding to factor VIIIa - Importance of helix 330 (helix 162 in chymotrypsin) of protease domain of factor IXa in its interaction with factor VIIIa

      JOURNAL OF BIOLOGICAL CHEMISTRY
    78. Russell, DW; Kay, MA
      Adeno-associated virus vectors and hematology

      BLOOD
    79. Hertzberg, MS; Facey, SL; Hogg, PJ
      An Arg Ser substitution in the second epidermal growth factor-like module of factor IX introduces an O-linked carbohydrate and markedly impairs activation by factor XIa and factor VIIa tissue factor and catalytic efficiency of factor IXa

      BLOOD
    80. Lozier, JN; Metzger, ME; Donahue, RE; Morgan, RA
      Rhesus macaque as an animal model for hemophilia B gene therapy

      BLOOD
    81. Wong, MY; Gurr, JA; Walsh, PN
      The second epidermal growth factor-like domain of human factor IXa mediates factor IXa binding to platelets and assembly of the factor X activating complex

      BIOCHEMISTRY
    82. LILLICRAP D
      THE MOLECULAR-BASIS OF HEMOPHILIA-B

      Haemophilia
    83. DiMichele, D; Neufeld, EJ
      Hemophilia - A new approach to an old disease

      HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
    84. STOYLOVA S; GRAY E; BARROWCLIFFE TW; KEMBALLCOOK G; HOLZENBURG A
      STRUCTURAL DETERMINATION OF LIPID-BOUND HUMAN BLOOD-COAGULATION FACTOR-IX

      Biochimica et biophysica acta. Protein structure and molecular enzymology
    85. WOJCIK EGC; CHEUNG WF; VANDENBERG M; VANDERLINDEN IK; STAFFORD DW; BERTINA RM
      IDENTIFICATION OF RESIDUES IN THE GLA-DOMAIN OF HUMAN FACTOR-IX INVOLVED IN THE BINDING TO CONFORMATION SPECIFIC ANTIBODIES

      Biochimica et biophysica acta. Protein structure and molecular enzymology
    86. FISCHER BE; DORNER F
      RECOMBINANT COAGULATION-FACTOR-IX - GLYCOSYLATION ANALYSIS AND IN-VITRO CONVERSION INTO HUMAN-LIKE SIALYLATION PATTERN

      Thrombosis research
    87. MARKLAND FS
      SNAKE-VENOMS AND THE HEMOSTATIC SYSTEM

      Toxicon (Oxford)
    88. CHANG JL; JIN JP; LOLLAR P; BODE W; BRANDSTETTER H; HAMAGUCHI N; STRAIGHT DL; STAFFORD DW
      CHANGING RESIDUE-338 IN HUMAN FACTOR-IX FROM ARGININE TO ALANINE CAUSES AN INCREASE IN CATALYTIC ACTIVITY

      The Journal of biological chemistry
    89. PERERA L; DARDEN TA; PEDERSON LG
      TRANS-CIS ISOMERIZATION OF PROLINE-22 IN BOVINE PROTHROMBIN FRAGMENT-1 - A SURPRISING RESULT OF STRUCTURAL CHARACTERIZATION

      Biochemistry
    90. SHIN Y; MORITA T
      RHODOCYTIN, A FUNCTIONAL NOVEL PLATELET AGONIST BELONGING TO THE HETERODIMERIC C-TYPE LECTIN FAMILY, INDUCES PLATELET-AGGREGATION INDEPENDENTLY OF GLYCOPROTEIN IB

      Biochemical and biophysical research communications
    91. CHENG CH; GENG JP; CASTELLINO FJ
      THE FUNCTIONS OF THE FIRST EPIDERMAL GROWTH-FACTOR HOMOLOGY REGION OFHUMAN PROTEIN-C AS REVEALED BY A CHARGE-TO-ALANINE SCANNING MUTAGENESIS INVESTIGATION

      Biological chemistry
    92. BJORKMAN S; CARLSSON M
      THE PHARMACOKINETICS OF FACTOR-VIII AND FACTOR-IX - METHODOLOGY, PITFALLS AND APPLICATIONS

      Haemophilia
    93. GILLIS S; FURIE BC; FURIE B; PATEL H; HUBERTY MC; SWITZER M; FOSTER WB; SCOBLE HA; BOND MD
      GAMMA-CARBOXYGLUTAMIC ACID-36 AND ACID-40 DO NOT CONTRIBUTE TO HUMAN FACTOR-IX FUNCTION

      Protein science
    94. THARIATH A; CASTELLINO FJ
      HIGHLY CONSERVED RESIDUE ARGININE-15 IS REQUIRED FOR THE CA2-DEPENDENT PROPERTIES OF THE GAMMA-CARBOXYGLUTAMIC ACID DOMAIN OF HUMAN ANTICOAGULATION PROTEIN-C AND ACTIVATED-PROTEIN-C()

      Biochemical journal
    95. ATODA H; YOSHIHARA E; YAMADA M; MORITA T
      CDNA CLONING OF A HETEROGENEOUS 2-CHAIN ANTICOAGULANT PROTEIN-IX-BP

      Thrombosis research
    96. BENITEZ BAS; HUNTER MJ; MEININGER DP; KOMIVES EA
      STRUCTURE OF THE 5TH EGF-LIKE DOMAIN OF THROMBOMODULIN - AN EGF-LIKE DOMAIN WITH A NOVEL DISULFIDE-BONDING PATTERN

      Journal of Molecular Biology
    97. MATHUR A; ZHONG DG; SABHARWAL AK; SMITH KJ; BAJAJ SP
      INTERACTION OF FACTOR IXA WITH FACTOR VIIIA - EFFECTS OF PROTEASE DOMAIN CA2-SITE, PROTEOLYSIS IN THE AUTOLYSIS LOOP, PHOSPHOLIPID, AND FACTOR-X( BINDING)

      The Journal of biological chemistry
    98. PERSSON E; OLSEN OH; OSTERGAARD A; NIELSEN LS
      CA2-LIKE DOMAIN OF FACTOR VIIA INCREASES AMIDOLYTIC ACTIVITY AND TISSUE FACTOR AFFINITY( BINDING TO THE FIRST EPIDERMAL GROWTH FACTOR)

      The Journal of biological chemistry
    99. WOLBERG AS; MORRIS DP; STAFFORD DW
      FACTOR-IX ACTIVATION BY FACTOR XIA PROCEEDS WITHOUT RELEASE OF A FREEINTERMEDIATE

      Biochemistry
    100. MANNUCCI PM
      THE CHOICE OF PLASMA-DERIVED CLOTTING FACTOR CONCENTRATES

      Bailliere's clinical haematology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/08/20 alle ore 02:08:19